EWTX Edgewise Therapeutics Inc
Price (delayed)
$28.01
Market cap
$2.67B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.45
Enterprise value
$2.63B
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.
Highlights
The EPS rose by 8% YoY and by 3.3% QoQ
Edgewise Therapeutics's equity has increased by 44% YoY but it has decreased by 6% from the previous quarter
The quick ratio has contracted by 24% from the previous quarter but it has grown by 3.8% YoY
The net income is down by 34% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of EWTX
Market
Valuations
Earnings
Shares outstanding
95.21M
Market cap
$2.67B
Enterprise value
$2.63B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$158.83M
Net income
-$133.81M
EBIT
-$133.81M
EBITDA
-$131.52M
Free cash flow
-$110.34M
Per share
Balance sheet
Liquidity
EPS
-$1.45
EPS diluted
-$1.45
Free cash flow per share
-$1.19
Book value per share
$4.85
Revenue per share
$0
TBVPS
$5.27
Total assets
$486.82M
Total liabilities
$27.6M
Debt
$4.74M
Equity
$459.22M
Working capital
$451.62M
Debt to equity
0.01
Current ratio
19.93
Quick ratio
19.71
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-25.7%
Return on equity
-26.8%
Return on invested capital
-28.7%
Return on capital employed
-28.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EWTX stock price
How has the Edgewise Therapeutics stock price performed over time
Intraday
-0.43%
1 week
7.03%
1 month
6.22%
1 year
57.89%
YTD
4.91%
QTD
4.91%
Financial performance
How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$158.83M
Net income
-$133.81M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 39% year-on-year and by 8% since the previous quarter
The net income is down by 34% year-on-year and by 8% since the previous quarter
Growth
What is Edgewise Therapeutics's growth rate over time
Valuation
What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
5.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 8% YoY and by 3.3% QoQ
The P/B is 114% more than the 5-year quarterly average of 2.7 and 34% more than the last 4 quarters average of 4.3
Edgewise Therapeutics's equity has increased by 44% YoY but it has decreased by 6% from the previous quarter
Efficiency
How efficient is Edgewise Therapeutics business performance
EWTX's ROIC is up by 22% YoY and by 2.7% QoQ
Edgewise Therapeutics's ROE has increased by 17% YoY
EWTX's ROA is up by 15% year-on-year
Dividends
What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EWTX.
Financial health
How did Edgewise Therapeutics financials performed over time
The total assets has grown by 43% YoY but it has contracted by 4.8% from the previous quarter
Edgewise Therapeutics's total liabilities has increased by 30% YoY and by 23% QoQ
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's debt to equity has shrunk by 50% YoY
Edgewise Therapeutics's equity has increased by 44% YoY but it has decreased by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.